Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEV-IP: Bevacizumab and CRS with Oxaliplatin for Colorectal Carcinomatosis
NCT02399410Phase 2Completed
- Sponsor
- Ghent University Hospital
- Start
- Nov 2015
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in colorectal cancer (CRC), sponsored by Ghent University Hospital. Primary endpoint: Surgical morbidity and mortality at 3 months. Started Nov 2015; status: completed.
02
Drugs
bevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02399410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02399410.